JTA NEWS
22 September 2019 - 22 Elul 5779 - כ"ב אלול ה' אלפים תשע"ט
JTA NEWS :
Business
Beijing airport selects Xsight Systems’ solution for runway safety E-mail

Beijing Capital International Airport, one of the busiest airports in the world, which handled over 100 million passengers in 2018, announced recently that it has selected Israel-based Xsight Systems, a global provider of advanced runway sensor-based solutions.

The airport has selected the FOD (Foreign Object Debris) Detection solution for installation on its East Runway. The FOD Detection system will help improve runway safety and capacity by continuously monitoring and detecting any forms of debris or hazards that could interfere with runway operations.

FOD and environmental threats on runways cost the global aviation industry nearly US$12 billion each year. RunWize, Xsight Systems’ Runway Management Solution, prevents many of the FOD incidents, bird strikes and runway excursions, thus increasing runway safety, capacity and efficiency. Amongst the leading airports using this technology are Boston Logan International Airport, Seattle-Tacoma International Airport, Tel-Aviv Ben-Gurion International Airport and Bangkok Suvarnabhumi International Airport. The Israeli Air Force has also adopted RunWize.

Please login or register to see the full article
 
India and Israeli collaborate on research in treatment of OSD Print E-mail

Israel-based Ocular Discovery and the All India Institute of Medical Sciences (AIIMS) in New Delhi have announced the launch of a novel research partnership investigating the mechanism of action of the drug Dipyridamole for various Ocular Surface Disorders (OSD).

Globally prescribed Dipyridamole, which has been used in the treatment of cardiovascular conditions for over 50 years, is already approved and available in Israel for the relief of various ocular conditions and disorders. The drug has shown marked symptomatic benefit in patients with pterygium and related dryeye symptoms, and also offers accessible and efficient delivery of the medication.

The research collaboration, led by Dr T. Velpandian, AIIMS, and Moshe Rogosnitzky, Ocular Discovery, seeks to investigate the effectiveness in the treatment and optimise dosage as a viable treatment option in the country.

(Issue May 2019)

 

 
IDE to build tallest office tower in Ramat Gan E-mail

The Israel Diamond Exchange (IDE) announced on 8 April that it plans to build a 120-storey tower within the Diamond Exchange complex in Ramat Gan Municipality. The tower will be the tallest in Israel and one of the ten tallest buildings in the world.

The building will expand the size of the Diamond Exchange complex to 800,000 sqm, from the 100,000 sqm it currently occupies. Bourse members will allocate some of the new area for use, and the rest will be leased to other business entities.

The project is being promoted by the Ramat Gan Municipality and will include two additional skyscrapers of 88 stories and 77 stories, expanding the number of towers on land owned by IDE to six.

According to Ramat Gan Mayor Carmel Shama-Hacohen, “The new compound will include the flagship tower of the State of Israel and will be the entrance gate to Ramat Gan.”

IDE President Yoram Dvash said: “We have a vision to expand and upgrade the complex to a bustling business centre and a bustling city centre for Ramat Gan, which is no less big and ambitious than the vision of the diamantaires in the 1960s. I was pleased to discover that the mayor is a partner to this vision.”

Please login or register to see the full article
 
South Korean firms invest in Weizmann Institute anti-cancer drug E-mail

An anti-cancer therapy that has been developed by scientists at the Weizmann Institute of Technology will receive a US$10 million investment from a South Korean biopharmaceutical company BioLeaders Corporation, which is traded on the Korea Stock Exchange. This is the firm’s first investment in an Israeli venture.

The Weizmann Institute also announced that a second sum of US$2 million will be invested by Yozma Group Asia, a VC fund, in On-Sight Medical Inc., jointly owned by Yeda Research, New York University (NYU) Medical School and other parties.

The institute said that the two Korean entities have committed to investing in two spinoff companies set up by Yeda Research and Development Co. Ltd., the technology transfer arm of the Weizmann Institute of Science.

BioLeaders Corporation, a clinical-stage biopharmaceutical firm, has signed a Letter of Intent with Yeda for the incorporation of a jointly owned company that will be set up in the coming months to develop the anti-cancer drug.

The drug will be based on the research of Weizmann Institute professors Varda Rotter and Moshe Oren, both of the Molecular Cell Biology Department.

Rotter and Oren were among the first to discover the function of the p53 protein – called the “guardian of the genome”. This protein is mutated or dysfunctional in over two-thirds of all cancers; such malfunctions can cause the cancer to spread faster. The two researchers recently developed a peptide – a small piece of protein – that can restore proper p53 function. The peptide they developed targets the malformed p53, and enters the cell and binds to the protein.

Please login or register to see the full article
 
Otonomo raising more funds from Asia E-mail

Israeli connected car company Otonomo is in the midst of its Series C financing round, according to Globes newswires. Sources close to the company said that it had already raised tens of millions of dollars, and that the round was likely to reach US$50-100 million this month.

Otonomo, founded by entrepreneur and CEO Ben Volkow, raised a total of US$43 million in its seed, A and B financing rounds.

South Korean group SK is leading the current round with a US$10 million investment. SK, the third-largest conglomerate in South Korea, has US$83.5 billion in annual revenue and 93,000 employees. Other undisclosed new investors are also investing in Otonomo, plus existing investors, such as Bessemer Venture Partners, StageOne Ventures, Maniv Mobility, Dell’s investment fund, international components supplier Delphi Partners and Japanese telecom giant NTT DoCoMo.

Figures published in the South Korean media, based on reports by SK, give Otonomo a value of US$370 million.

Ontonomo has developed a cloud platform for autonomous vehicles that gathers information from vehicles on the roads, compiles it, processes it on the cloud, and commercialises it.

The information includes details about how the driver drives, his/her location in the vehicle, the physical state and maintenance of vehicles, the level of air pressure in the tyres, and even the type of media the driver and passengers in the car consume.

Please login or register to see the full article
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>


Warning: Parameter 1 to modMainMenuHelper::buildXML() expected to be a reference, value given in /home/joomla789/domains/jewishtimesasia.org/public_html/libraries/joomla/cache/handler/callback.php on line 99
Jewish Times Asia is published by Jewish Times Asia Ltd. © Copyright 2019.
Material in the newspaper or on this site may not be used or reproduced in any form or in any way without permission from the editor.
While every effort has been made to ensure the content is true and accurate, the publisher is not responsible for any errors or omissions in the printed text.